SOLID TUMORS

This study tests a personalized vaccine made from each patient's unique tumor mutations. The vaccine is designed to train the immune system to attack the cancer. Ten adults with advanced or high-risk solid tumors will receive the vaccine along with immune-boosting drugs. The goal…

This early-stage study tests a new drug (ORIC-114) combined with an existing targeted therapy (amivantamab) in people with advanced lung cancer that has a specific genetic change (EGFR Exon20 insertion). The goal is to find the safest dose and see if the combination shrinks tumor…

This early-phase trial tests a new oral drug, Aza-TdC, in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can turn on genes that may slow tumor growth. Participants take the drug in 21-day cycle…

This early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in 450 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to check safety and see if the drugs shrink tumors. Participants must be in fairly go…

This study tests whether dapagliflozin, a medicine used for diabetes, can prevent kidney damage in people receiving platinum-based chemotherapy for solid tumors. About 46 participants will receive either dapagliflozin or a placebo, and researchers will measure kidney injury marke…

This early-phase study tests a new treatment called TX103 CAR-T cells for people with advanced solid tumors that have not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals …

This early-stage trial tests a new drug, QTX3034, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goal is to check the drug's safety and find the right dose, either alone or with another drug called cetuximab. About 250 adults w…

This early-stage trial tests a new drug, VLPONC-01, injected directly into tumors in people with head and neck cancer. The study aims to see if it is safe and whether combining it with an immunotherapy drug (pembrolizumab) can shrink tumors better than the immunotherapy alone. Ab…

This early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and watch for side effects. Up to 54 particip…

This study tests a new drug called JAB-2485 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 102 people will take part in this early-phase trial.

This early-stage study tests an experimental drug called GSK5733584 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also see if the drug can shrink tumors. …

This study tests a new drug called 7MW4911 in 200 people with advanced solid tumors that have worsened after standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is the first time this drug is being tested in human…

This study looks at the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in up to 3,500 people with solid tumors or blood cancers who have already been in a Merck study with this drug. Participants continue their treatment or follow-up as before, wit…

This study tests an experimental drug called FORE8394 (plixorafenib) in people aged 10 and older whose cancers have specific BRAF gene changes. It includes solid tumors, brain tumors, and melanomas that have not responded to standard treatments. The goal is to see if the drug shr…

This study tests an experimental drug called ICP-723 in adults and teenagers with advanced solid tumors that cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 310 participants will take part i…

This study tests two drugs, envafolimab and lenvatinib, together in people with advanced solid tumors (lung, kidney, or liver cancer) that have stopped responding to standard treatments. The goal is to see if the combination can shrink tumors better than current options. About 17…

This early-stage study tests a new drug, AUBE00, in about 90 to 130 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have a spec…

This early-phase study tests a new drug called INCA33890 in about 408 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their g…

This early-phase study tests a new oral drug, TYRA-430, in about 100 adults with advanced liver cancer or other solid tumors that have specific FGF/FGFR gene changes. The main goals are to find the safest dose and check for side effects. Researchers will also look for early signs…

This early-phase study tests a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to specific proteins on cancer cells and deliver a chemotherapy-like payload directly to them. The main goal…

This early-stage study tests a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also measure how the drug …

This early-phase study tests a new drug called INCB123667, alone or with other cancer treatments, in adults with advanced solid tumors that have stopped responding to standard care. The main goals are to check safety, find the right dose, and see if the drug can help control the …

This study tests an experimental drug, ZL-1310, in about 112 adults with advanced neuroendocrine carcinomas that have worsened after standard chemotherapy. The goal is to see if the drug can shrink tumors and to check for side effects. Participants will receive the drug and be mo…

This study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …

This early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.

This early-phase study tests a new drug, INCA036873, in adults with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The main goal is to check the drug's safety and find the right dose. About 280 participants will take part across multip…

This early-stage trial tests a new cell treatment called GK01, given alone or with chemotherapy, for people with advanced solid tumors like pancreatic or stomach cancer. The main goal is to check safety and how the body handles the treatment. About 15 participants will be enrolle…

This study tests a new drug called SOA101 in people with advanced solid tumors (like lung, ovarian, or breast cancer) who have no other treatment options. The drug is a special antibody designed to help the immune system attack cancer cells. The study aims to find the safest dose…

This early-phase study tests a new drug called INCB161734, alone or with other cancer treatments, in people with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check safety and find the right dose. About 710 adults whose cancer has worsened a…

This study tests a new drug called S-531011, alone or with other cancer treatments, in people with advanced solid tumors that have not responded to standard therapies. The goal is to find safe doses and see if the drug can shrink tumors or slow their growth. About 282 adults with…

This early-stage trial tests a new drug, GEN1106, in about 103 people with solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants receive the active drug…

This study tests a new drug called HRS-7058 combined with other anti-tumor medicines in people with solid tumors. The goal is to see if the combination is safe and tolerable, and to find the best dose. About 100 adults aged 18 to 75 with solid tumors will take part. The study wil…

This early-stage study tests a new drug, XB371, in about 150 people with advanced solid tumors that have come back or spread. The main goal is to check the drug's safety and find the best dose. Participants must be in fairly good health and have a life expectancy of at least 12 w…

This study tests whether adding the experimental drug INCB161734 to standard chemotherapy helps people with a certain genetic form of advanced pancreatic cancer (KRAS G12D mutation) live longer and keep the cancer from growing. About 588 adults who have not had prior treatment fo…

This study tests an experimental drug called SHR-4610 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink or control tumors. About 258 participants will take part across two phases.

This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the dru…

This study tests a combination of drugs (liposomal mitoxantrone, capecitabine, and anlotinib) in children, teens, and young adults whose solid tumors have returned or not responded to treatment. The goal is to see if this combo can shrink tumors and control the disease. Participa…

This early-phase study tests a new radioactive drug called Lutetium BL-ARC001 in 22 people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it helps shrink tumors. Participants must have tumo…

This study tests a new drug called DCSZ11 alongside standard treatments for people with advanced or metastatic solid tumors, including head and neck cancer. The goal is to see if the combination can shrink tumors or keep them from growing. About 9 adults will take part, and the f…

This early-phase study tests a new drug called PEP08 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 40 adults will receive PEP08 alone or w…

This early-phase study tests a new drug that delivers radiation directly to cancer cells in people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for early signs of …

This early-stage study tests a new drug called BL-ARC002 in 22 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the disease. Participants will receiv…

This study tests an experimental drug called JAB-30355 in adults with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe, tolerable, and shows signs of shrinking tumors. About 144 participants will receive the drug, and research…

This study tests a drug called romiplostim N01 to help children and young adults (ages 6-24) with cancer whose platelet counts drop dangerously low after chemotherapy. Low platelets can cause bleeding and delay treatment. The drug is given as a weekly shot to boost platelet produ…

This early-phase study tests a new drug called HDM2017 in about 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must be 18-75 and …

This early-phase study tests a new drug called BL-M24D1 in about 33 people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants must have tried other treatme…

This study offers continued treatment with the drug adagrasib to cancer patients who have already been benefiting from it in earlier studies. It is for people with advanced solid tumors like lung or colorectal cancer. The main goal is to monitor safety and side effects over the l…

This study gives people who are already benefiting from the cancer drugs encorafenib and/or binimetinib in earlier trials continued access to these medicines for up to 5 years. It includes safety monitoring and is open to about 46 participants whose doctors confirm they are still…

This early-stage study tests a new drug called casdatifan (AB521) in people with advanced kidney cancer or other solid tumors. The goal is to find safe doses and see if the drug works better alone or with other treatments. About 362 participants will join this study to help deter…

This early-stage trial tests a new drug called JR8603 in about 94 adults with advanced solid tumors (including stomach, junction, and colorectal cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug ca…

This program provides early access to telisotuzumab adizutecan for people with solid tumors who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by local regu…

This study tests whether a single injection of Telpegfilgrastim works better than daily Filgrastim shots to prevent fever and low white blood cells in children and young adults (ages 6-24) with solid tumors receiving strong chemotherapy. About 132 participants will receive either…

This study tests a new drug (ABL103) combined with an existing immunotherapy (pembrolizumab) and sometimes a chemotherapy (taxane) in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and can shrin…

This early-phase study tests a new oral drug, DPTX3186, in 40 adults with advanced solid tumors (like colorectal, lung, or breast cancer) that have a specific genetic change (Wnt pathway) and no remaining standard treatments. The main goals are to check safety and how the drug mo…

This early-stage study tests a new drug called HS-20110 in adults with advanced solid tumors that have not responded to other treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 475 participants will take part across multiple centers.

This early-stage study tests a new drug called HRS-6208 in about 206 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow cancer growth. Participants…

This study tests a drug called ponatinib in children aged 1 to 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to other treatments. The goal is to see if the drug is safe and can shrink or control the cancer. About 70 children will take…

This study tests a new drug called RC278 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 312 adults aged 18 to 75 with good organ function are being recruite…

This study is testing a new type of PET/CT scan that uses a special probe (89Zr-s-C1) to find solid tumors in the body. The probe targets a protein called MUC18, which is found on some cancer cells. The goal is to see if this scan can find tumors that standard scans might miss, h…

This early-stage study tests a new radioactive dye called RT01-89Zr that attaches to a protein found on many solid tumor cells. The goal is to see if it can safely and clearly show tumors on PET/CT scans. Ten adults with advanced solid tumors will receive the dye and be monitored…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are getting chemotherapy. The drug aims to boost white blood cells, reducing the risk of severe infections. Researchers will check how safe the drug is and how the body processes it.

This study is collecting information from 1,000 people with solid tumors who receive chemotherapy through a special catheter called RenovoCath, which delivers drugs directly to the tumor site. Researchers are tracking safety, side effects, and survival over time. The goal is to l…

This study is collecting medical information and biological samples from 15,000 people receiving radiation therapy for cancer. Researchers want to understand how radiation affects side effects, quality of life, and survival over time. Participants must be treated with curative in…

This study aims to find a way to predict serious side effects from cancer immunotherapy, which can make the immune system attack healthy tissues. Researchers will collect blood samples from 300 cancer patients starting immunotherapy and 40 people with autoimmune diseases like lup…

This study aims to find abnormal genes (mutations) in cancer cells using leftover tumor tissue from past surgeries or biopsies. Participants also give a blood, cheek swab, or saliva sample for comparison. The goal is to understand how these genetic changes affect response to expe…

This study is for adults with certain advanced solid tumors (non-small cell lung cancer, colorectal cancer, or ovarian cancer). Researchers want to find biological markers that show how the experimental drug SAR444881 works, alone or with cemiplimab. About 40 participants will re…